Sulfasalazine and pentoxifylline in psoriasis: A possible safe alternative

References

• Linden KG, Weinstein GD. Psoriasis: Current perspectives with an emphasis on treatment. Am J Med. 1999;107:595–605.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Menter A, Koo J, Feldman SR. Combination therapy to treat moderate to severe psoriasis. J Am Acad Dermatol. 2004;50:416–430.
   PubMed Web of Science ®Google Scholar
• Lebwohl M. Psoriasis. In: Lebwohl M, Heymann WR, Berth-Jones J, Coulson I, editors. Treatment of skin diseases. Comprehensive therapeutic strategies. 1st ed. Mosby International; London 2002. p. 533–543.
   Google Scholar
• Shanahan F, Niederlehner A, Carramanzana N, Anton P. Sulfasalazine inhibits the binding of TNF alpha to its receptor. Immunopharmacology. 1990;20(3):217–224.
   PubMedGoogle Scholar
• Pruzanski W, Stefanski E, Vadas P, Ramamurthy NS. Inhibition of extracellular release of proinflammatory secretory phospholipase A2 (sPLA2) by sulfasalazine: A novel mechanism of anti-inflammatory activity. Biochem Pharmacol. 1997;53(12):1901–1907.
   PubMed Web of Science ®Google Scholar
• Neuner P, Klosner G, Schauer E, Pourmojib M, Macheiner W, Grünwald C, Pentoxifylline in vivo down-regulates the release of IL-1 beta, IL-6, IL-8 and tumour necrosis factor-alpha by human peripheral blood mononuclear cells. Immunology. 1994;83(2):262–267.
   PubMed Web of Science ®Google Scholar
• El-Darouti M, Marzouk S, Abdel Hay R, El Tawdy A, Fawzy M, Leheta T, The use of sulfasalazine and pentoxifylline (low-cost antitumour necrosis factor drugs) as adjuvant therapy for the treatment of pemphigus vulgaris: A comparative study. Br J Dermatol. 2009;161(2):313–319. Epub 2009 Apr 10.
   PubMed Web of Science ®Google Scholar
• Gilhar A, Grossman N, Kahanovicz S, Reuveni H, Cohen S, Eitan A. Antiproliferative effect of pentoxifylline on psoriatic and normal epidermis. In vitro and in vivo studies. Acta Derm Venereol. 1996;76(6):437–441.
   PubMed Web of Science ®Google Scholar
• Franklin JL, Rosenberg HH. Impaired folic acid absorption in inflammatory bowel disease: Effects of salicylazosulfapyridine (Azulfidine). Gastroenterology. 1973;64(4):517–525.
   PubMed Web of Science ®Google Scholar
• Halsted CH, Gandhi G, Tamura T. Sulfasalazine inhibits the absorption of folates in ulcerative colitis. N Engl J Med. 1981;305(25):1513–1517.
   PubMed Web of Science ®Google Scholar
• Jones G, Crotty M, Brooks P. Interventions for psoriatic arthritis. Cochrane Database Syst Rev. 2000;((3):CD000212.
   Google Scholar
• Marguerie L, Flipo RM, Grardel B, Beaurain D, Duquesnoy B, Delcambre B. Use of disease-modifying antirheumatic drugs in patients with psoriatic arthritis. Joint Bone Spine. 2002;69(3):275–281.
   PubMed Web of Science ®Google Scholar
• Gupta AK, Ellis CN, Siegel MT, Voorhees JJ. Sulfasalazine: A potential psoriasis therapy? J Am Acad Dermatol. 1989;20(5 Pt 1):797–800.
   PubMed Web of Science ®Google Scholar
• Gupta AK, Ellis CN, Siegel MT, Duell EA, Griffiths CE, Hamilton TA, Sulfasalazine improves psoriasis. A double-blind analysis. Arch Dermatol. 1990;126(4):487–493.
   PubMedGoogle Scholar
• Omulecki A, Broniarczyk-Dyła G, Zak-Prelich M, Choczaj-Kukuła A. Is pentoxifylline effective in the treatment of psoriasis? J Am Acad Dermatol. 1996;34(4):714–715.
   PubMed Web of Science ®Google Scholar
• Magela Magalhães G, Coelho da Silva Carneiro S, Peisino do Amaral K, de Freire Cássia F, Machado-Pinto J, Cuzzi T. Psoriasis and pentoxifylline: A clinical, histopathologic, and immunohistochemical evaluation. Skinmed. 2006;5(6):278–284.
   PubMedGoogle Scholar
• Marks R, Barton S, Shuttelworth D, Finlay AY. Assessment of disease progress in psoriasis. Arch Dermatol. 1989;125:235–240.
   PubMedGoogle Scholar
• Baumgartner TA, Strong CH. Conducting and reading research in health and human performances. 2nd ed. McGraw Hill; Colombus USA 1998.
   Google Scholar
• Zargari O. Pentoxifylline: A drug with wide spectrum applications in dermatology. Dermatol Online J. 2008;14(11):2.
   PubMedGoogle Scholar
• Van Furth AM, Verhard-Seijmonsbergen EM. Effect of lisofylline and pentoxifylline on the bacterial-stimulated production of TNF-alpha, IL-1 beta IL-10 by human leucocytes. Immunology. 1997;91:193–196.
   PubMed Web of Science ®Google Scholar
• Strieter RM, Remick DG, Ward PA, Spengler RN, Lynch JP, Larrick J, Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem Biophys Res Commun. 1988;155:1230–1236.
   PubMed Web of Science ®Google Scholar
• Kano Y, Hirayama K, Orihara M, Shiohara T. Successful treatment of Schamberg's disease with pentoxifylline. J Am Acad Dermatol. 1997;36:827–830.
   PubMed Web of Science ®Google Scholar
• Bruynzeel I, van der Raaij LM, Willemze R, Stoof TJ. Pentoxifylline inhibits human T-cell adhesion to dermal endothelial cells. Arch Dermatol Res. 1997;289(4):189–193.
   PubMed Web of Science ®Google Scholar
• Cohen KL, Lucibello FE, Chomiak M. Lack of effect of clonidine and pentoxifylline in short-term therapy of diabetic peripheral neuropathy. Diabetes Care. 1990;13:1074–1077.
   PubMed Web of Science ®Google Scholar
• Lee SS, Ang P, Tan SH. Clinical profile and treatment outcome of livedoid vasculitis: A case series. Ann Acad Med Singapore. 2003;32:835–839.
   PubMed Web of Science ®Google Scholar
• Bissonnette EY, Enciso JA, Befus AD. Inhibitory effects of sulfasalazine and its metabolites on histamine release and TNF-alpha production by mast cells. J Immunol. 1996;156:218–223.
   PubMed Web of Science ®Google Scholar
• Bessler H, Gilgal R, Djaldetti M, Zahavi I. Effect of pentoxifylline on the phagocytic activity, cAMP levels, and superoxide anion production by monocytes and polymorphonuclear cells. J Leukoc Biol. 1986;40:747–754.
   PubMed Web of Science ®Google Scholar
• Dewit O, Vanheuverzwyn R, Desager JP, Horsmans Y. Interaction between azathioprine and aminosalicylates: An in vivo study in patients with Crohn's disease. Aliment Pharmacol Ther. 2002;16:79–85.
   PubMed Web of Science ®Google Scholar
• Raoul JM, Peterson MR, Peterson TC. A novel drug interaction between the quinolone antibiotic ciprofloxacin and a chiral metabolite of pentoxifylline. Biochem Pharmacol. 2007;74:639–646.
   PubMed Web of Science ®Google Scholar
• Ashcroft DM, Wan Po AL, Williams HC, Griffiths CE. Clinical measures of disease severity and outcome in psoriasis: A critical appraisal of their quality. Br J Dermatol. 1999;141:185–191.
   PubMed Web of Science ®Google Scholar
• Weisman S, Pollack CR, Gottschalk RW. Psoriasis disease severity measures: Comparing efficacy of treatments for severe psoriasis. J Dermatolog Treat. 2003;14:158–165.
   PubMedGoogle Scholar